0001104659-22-002471.txt : 20220110 0001104659-22-002471.hdr.sgml : 20220110 20220110070020 ACCESSION NUMBER: 0001104659-22-002471 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220110 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220110 DATE AS OF CHANGE: 20220110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nabriva Therapeutics plc CENTRAL INDEX KEY: 0001641640 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37558 FILM NUMBER: 22519619 BUSINESS ADDRESS: STREET 1: 25-28 NORTH WALL QUAY CITY: DUBLIN STATE: L2 ZIP: D01 H104 BUSINESS PHONE: (610) 816-6640 MAIL ADDRESS: STREET 1: 414 COMMERCE DRIVE STREET 2: STE 120 CITY: FORT WASHINGTON STATE: PA ZIP: 19034 FORMER COMPANY: FORMER CONFORMED NAME: Nabriva Therapeutics AG DATE OF NAME CHANGE: 20150507 8-K 1 tm222155d2_8k.htm FORM 8-K
0001641640 false 00-0000000 00000 0001641640 2022-01-10 2022-01-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of Earliest Event Reported): January 10, 2022

 

NABRIVA THERAPEUTICS PLC

(Exact name of registrant as specified in its charter)

 

Ireland   001-37558   Not Applicable
(State or other jurisdiction of
incorporation)		   (Commission File Number)   (I.R.S. Employer Identification No.)

 

25-28 North Wall Quay,
IFSC, Dublin 1, Ireland		   Not Applicable
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (610) 816-6640

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
Ordinary Shares, nominal value $0.01 per share   NBRV   The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o

 

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On January 10, 2022, Nabriva Therapeutics plc (the “Company”) issued a press release announcing preliminary financial results for the fourth quarter of 2021. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 8.01. Other Events.

 

Preliminary Financial Results

 

As described above, on January 10, 2022, the Company announced that, although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2021, it expects to report cash, cash equivalents and short-term investments of approximately $47.7 million as of December 31, 2021. In addition, the Company expects to report that total revenue for the fourth quarter of 2021 grew at a mid-to-high single digit percentage versus third quarter of 2021’s reported total revenue of $8.9 million.

 

These estimated financial results are preliminary and unaudited, represent management’s estimates as of the date of this Current Report on Form 8-K and are subject to the completion of the Company’s financial closing procedures. The Company’s independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, these estimated financial results.

 

Cash Runway

 

As a result of SIVEXTRO sales in the fourth quarter of 2021 and improved operating efficiencies within the business, the Company anticipates that its cash, cash equivalents and short-term investments as of December 31, 2021 will be sufficient to enable it to fund its operations, debt service obligations and capital expenditure requirements well into the fourth quarter of 2022. The Company has based this estimate on assumptions that may prove to be wrong, and it could use its capital resources sooner than it currently expects.

 

Clinical Update

 

The Company has initiated a Phase I clinical trial of lefamulin for the treatment of cystic fibrosis patients with bacterial infections and expects to enroll the first patient in the trial in the first quarter of 2022.

 

Forward-Looking Statements

 

Any statements in this Current Report on Form 8-K about future expectations, plans and prospects for the Company, including but not limited to statements about the sufficiency of the Company’s existing cash resources, its preliminary financial results for the fourth quarter of 2021, the timing of patient enrollment for its Phase I clinical trial and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the extent of business and other interruptions resulting from the infection causing the COVID-19 outbreaks or similar public health crises, the sufficiency of cash resources and need for additional financing and such other important factors as are set forth in the Company’s annual and quarterly reports and other filings with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this Form 8-K represent the Company’s views as of the date of this Form 8-K. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this Form 8-K.

 

 

 

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit
No.		   Description
99.1   Press Release dated January 10, 2022
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  NABRIVA THERAPEUTICS PLC
     
Date: January 10, 2022 By: /s/ Daniel Dolan
    Daniel Dolan
    Chief Financial Officer

 

 

 

 EX-99.1 2 tm222155d2_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

Nabriva Therapeutics Provides Business Update and Announces Preliminary Financial Results for the Fourth Quarter of 2021

 

-SIVEXTRO® (tedizolid phosphate) remains on track for return to historical peak sales by mid-2022-

 

-XENLETA® (lefamulin) Phase I Cystic Fibrosis (CF) trial on track to enroll first patient in Q122-

 

-Cash resources of $47.7 million as of 12/31/21 provides cash runway well into Q422-

 

DUBLIN, Ireland and Fort Washington, Pa., January 10, 2022 -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced a business update today and preliminary, unaudited financial results for the fourth quarter of 2021.

 

“We made excellent progress in 2021 in spite of the COVID pandemic and are poised for continued growth in 2022,” commented Ted Schroeder, Chief Executive Officer of Nabriva Therapeutics. “We had a strong close to 2021 for SIVEXTRO, which contributed to extending our cash runway well into the fourth quarter of 2022 and we continue to propel the product back to historical prescription trends through our promotional efforts.” Mr. Schroeder continued, “while our commercialization efforts for XENLETA have faced significant headwinds due to the global pandemic, we remain focused on maximizing the value of this novel, first-in-class antibacterial agent in the U.S. through our focused commercial investments, and outside the U.S. by expanding our partnerships globally.”

 

“We have also made significant progress in executing on life-cycle management opportunities for XENLETA with the initiation of a Phase I trial for CF and early-stage work focused on drug-resistant sexually transmitted infections and other unmet medical conditions for this important drug.” Mr. Schroeder added, “we stand ready to resubmit our New Drug Application for CONTEPO and potentially bring this important antibiotic to the U.S. market once COVID-related travel restrictions are lifted and the U.S. Food and Drug Administration (FDA) is able to complete inspections of our manufacturing partners in the European Union.”

 

In 2021, we positioned the growth of our business by:

 

·Launching Nabriva’s own National Drug Code (NDC) of SIVEXTRO in April 2021

·Reporting positive Phase III trial results for lefamulin in China in May 2021

·Transitioning lefamulin commercial rights in China to Sumitomo Pharmaceuticals in May 2021

·Receiving approval of lefamulin in Taiwan in September 2021

·Contracting with Vizient Health in September 2021 to enhance access for XENLETA

·Publishing data on anti-inflammatory effects of lefamulin in PLOS ONE in November 2021

·Achieving acceptance of our New Drug Application by the National Medical Products Administration (NMPA) in China in November 2021

·Launching a 10-count blister pack or “X Pack” of XENLETA in November 2021 to improve distribution and customer access

 

 

 

 

In 2022, we look for continued growth through execution on key milestones including:

 

·Growing SIVEXTRO sales to historical levels by mid-2022

·Pulling through hospital transition of care opportunity for XENLETA with Vizient Health

·Enrolling the first patient in our Phase I CF trial in the first quarter

·Geographic expansion of commercialization and distribution partnerships for lefamulin in the EU and the rest of the world

·Continuing to work with FDA to bring CONTEPO to market in the U.S.

·Assessing other business development opportunities to add to our product portfolio and leverage current infrastructure

 

Preliminary Financial Results

 

The company enters 2022 with $47.7 million of cash, cash equivalents and short-term investments as of December 31, 2021 compared to $52.2 million of cash, cash equivalents and short-term investments as of September 30, 2021. As a result of the strong close to 2021 for SIVEXTRO sales, and improved operating efficiencies within the business, our cash balance as of December 31, 2021 is expected to fund our operations, debt service obligations and capital expenditure requirements well into the fourth quarter of 2022. In addition, we anticipate reporting that total revenue for the fourth quarter of 2021 grew at a mid-to-high single digit percentage versus third quarter of 2021’s reported total revenue of $8.9 million.

 

These estimated financial results are preliminary and unaudited, represent management’s estimates as of the date of this press release and are subject to completion of Nabriva’s financial closing procedures. Nabriva’s independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, these estimated financial results.

 

About Nabriva Therapeutics plc

 

Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories.

 

About XENLETA

 

XENLETA (lefamulin) is a first-in-class semi-synthetic pleuromutilin antibiotic for systemic administration in humans discovered and developed by the Nabriva Therapeutics team. It is designed to inhibit the synthesis of bacterial protein, which is required for bacteria to grow. XENLETA’s binding occurs with high affinity, high specificity and at molecular sites that are different than other antibiotic classes. Efficacy of XENLETA was demonstrated in two multicenter, multinational, double-blind, double-dummy, non-inferiority trials assessing a total of 1,289 patients with CABP. In these trials, XENLETA was compared with moxifloxacin and in one trial, moxifloxacin with and without linezolid. Patients who received XENLETA had similar rates of efficacy as those taking moxifloxacin alone or moxifloxacin plus linezolid. The most common adverse reactions associated with XENLETA included diarrhea, nausea, reactions at the injection site, elevated liver enzymes, and vomiting. For more information, please visit www.XENLETA.com.

 

 

 

 

About SIVEXTRO

 

SIVEXTRO (tedizolid phosphate) was approved by the U.S. Food and Drug Administration in 2014. It is indicated in adults and pediatric patients 12 years of age and older for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group (including Streptococcus anginosus, Streptococcus intermedius and Streptococcus constellatus), and Enterococcus faecalis. To reduce the development of drug-resistant bacteria and maintain the effectiveness of SIVEXTRO and other antibacterial drugs, SIVEXTRO should be used only to treat ABSSSI that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

 

Forward-Looking Statements

 

Any statements in this press release about future expectations, plans and prospects for Nabriva Therapeutics, including but not limited to statements about its preliminary financial results for the fourth quarter of 2021, the timing of patient enrollment for its planned Phase I clinical trial of lefamulin for CF, the potential for, and timing of, SIVEXTRO’s return to historical peak sales, its ability to successfully commercialize XENLETA for the treatment of CABP, including the managed care coverage for XENLETA, the distribution and promotion of SIVEXTRO for the treatment of ABSSSI, the development of CONTEPO for Complicated Urinary Tract Infections (cUTI), the clinical utility of XENLETA for CABP, SIVEXTRO for ABSSSI and of CONTEPO for cUTI, the impact of macro events on sales of SIVEXTRO and XENLETA, plans for and timing of the review of regulatory filings for XENLETA and CONTEPO, efforts to bring CONTEPO to market, the market opportunity for and the potential market acceptance of XENLETA for CABP, SIVEXTRO for ABSSSI and CONTEPO for cUTI, the development of XENLETA and CONTEPO for additional indications, plans for making lefamulin available in the European Union, Canada and China, plans to pursue research and development of other product candidates, plans to pursue business development initiatives, expectations regarding the impact of the interruptions resulting from COVID-19 on its business, the sufficiency of Nabriva Therapeutics’ existing cash resources and its expectations regarding anticipated revenues from product sales and how far into the future its existing cash resources will fund its ongoing operations and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: Nabriva Therapeutics’ ability to successfully implement its commercialization plans for XENLETA and SIVEXTRO and whether market demand for XENLETA and SIVEXTRO is consistent with its expectations, Nabriva Therapeutics’ ability to build and maintain a sales force for XENLETA and SIVEXTRO, the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, the uncertainties inherent in the initiation and conduct of clinical trials, availability and timing of data from clinical trials, whether results of early clinical trials or studies in different disease indications will be indicative of the results of ongoing or future trials, uncertainties associated with regulatory review of clinical trials and applications for marketing approvals, the availability or commercial potential of CONTEPO for the treatment of cUTI, the extent of business interruptions resulting from the infection causing the COVID-19 outbreak or similar public health crises, the ability to retain and hire key personnel, the availability of adequate additional financing on acceptable terms or at all and such other important factors as are set forth in Nabriva Therapeutics’ annual and quarterly reports and other filings on file with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Nabriva Therapeutics’ views as of the date of this press release. Nabriva Therapeutics anticipates that subsequent events and developments will cause its views to change. However, while Nabriva Therapeutics may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Nabriva Therapeutics’ views as of any date subsequent to the date of this press release.

 

CONTACTS:

 

For Investors

Kim Anderson

Nabriva Therapeutics plc

ir@nabriva.com

 

 

 

 EX-101.SCH 3 nbrv-20220110.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 nbrv-20220110_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 nbrv-20220110_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm222155d2_ex99-1img01.jpg GRAPHIC begin 644 tm222155d2_ex99-1img01.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Cover
Jan. 10, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 10, 2022
Entity File Number 001-37558
Entity Registrant Name NABRIVA THERAPEUTICS PLC
Entity Central Index Key 0001641640
Entity Tax Identification Number 00-0000000
Entity Incorporation, State or Country Code L2
Entity Address, Address Line One 25-28 North Wall Quay
Entity Address, Address Line Two IFSC
Entity Address, City or Town Dublin 1
Entity Address, Country IE
Entity Address, Postal Zip Code 00000
City Area Code 610
Local Phone Number 816-6640
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Ordinary Shares, nominal value $0.01 per share
Trading Symbol NBRV
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm222155d2_8k_htm.xml IDEA: XBRL DOCUMENT 0001641640 2022-01-10 2022-01-10 iso4217:USD shares iso4217:USD shares 0001641640 false 00-0000000 00000 8-K 2022-01-10 NABRIVA THERAPEUTICS PLC L2 001-37558 25-28 North Wall Quay IFSC Dublin 1 IE 610 816-6640 false false false false Ordinary Shares, nominal value $0.01 per share NBRV NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 1 122 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://nabriva.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm222155d2_8k.htm nbrv-20220110.xsd nbrv-20220110_lab.xml nbrv-20220110_pre.xml tm222155d2_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm222155d2_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm222155d2_8k.htm" ] }, "labelLink": { "local": [ "nbrv-20220110_lab.xml" ] }, "presentationLink": { "local": [ "nbrv-20220110_pre.xml" ] }, "schema": { "local": [ "nbrv-20220110.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 122, "memberCustom": 0, "memberStandard": 0, "nsprefix": "nbrv", "nsuri": "http://nabriva.com/20220110", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm222155d2_8k.htm", "contextRef": "From2022-01-10to2022-01-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://nabriva.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm222155d2_8k.htm", "contextRef": "From2022-01-10to2022-01-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nabriva.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 16 0001104659-22-002471-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-002471-xbrl.zip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end